Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”

Abstract

Abdullah Kaya Department of Ophthalmology, Anittepe Military Dispensary, Ankara, TurkeyI read the current article titled “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes” by Razi et al,1 with great interest. View the original article by Razi et al

Keywords

• ranibizumab
• anti-VEGF
• age related macular degeneration
• visual acuity
• injection